Helpful budget16 Mar 2023 08:33
Few things might benefit avacta
A ยฃ500 million per year package of support for 20,000 research and development (R&D) intensive businesses through changes to R&D tax credits.
The Medicines and Healthcare products Regulatory Agency (MHRA) will receive ยฃ10 million extra funding over two years to maximise its use of Brexit freedoms and accelerate patient access to treatments. This will allow, from 2024, the MHRA to introduce new, swift approvals systems, speeding up access to treatments already approved by trusted international partners and ground-breaking technologies such as cancer vaccines and AI therapeutics for mental health.
Medicines and Healthcare products Regulatory Agency (MHRA) recognition framework โ The government is providing ยฃ10 million extra funding in 2023-24 to 2024-25 to the MHRA, allowing the regulator to maximise its use of Brexit freedoms and accelerate patient access to treatments. From 2024, MHRA will have a fully operational swift approval process for the most impactful new medicines and technologies. The MHRA is also exploring partnerships with trusted international agencies, such as the U.S., Europe and Japan to provide simple, rapid approvals for medicines and technologies from 2024.